Ulcerative Colitis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Ulcerative Colitis remains an active clinical development field. Clinical competition is shifting from broad immunosuppression toward pathway-selective control, durable remission and treatment strategies that reduce steroid exposure without trading away safety. The PatSnap evidence set used here contains 1,245 matched trial records and 1,470 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07700446 | Upadacitinib hemihydrate | Phase 4; Not yet recruiting | Sponsor not listed | Geography not listed | To determine the rate of re-capture of clinical response per adapted Mayo score at week 8 or week 16 (pooled). (Baseline, week8 and 16) | 2029-11-01 |
| NCT07697456 | FG-M701 + Risankizumab-RZAA | Phase 2; Not yet recruiting | AbbVie, Inc. | Belgium, United States, Japan, South Africa, Slovenia +4 more | Crohn's Disease Specific: Percentage of Participants Achieving Endoscopic Remission (At Week 28); Ulcerative Colitis Specific: Percentage of Participants who Achieve Endoscopic Remission (At Week 28) | 2031-10-01 |
| CTR20262583 | AC-101 | Phase 2; 进行中 （尚未招募） | Accro Bioscience (Suzhou) Co., Ltd. | China | (第12周) | Timing not listed |
| NCT07694609 | Intervention not normalized | Not Applicable; Active, not recruiting | Sponsor not listed | Italy | Change in Work Ability Index (WAI) Score From Baseline to 12 Months (Baseline and 12 months) | 2027-10-23 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- Randomized, Double-blind, Phase 2 Study to Evaluate the Efficacy and the Safety of OSE-127 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Previous Treatment(s) (Phase 2): the indexed record reports Change From Baseline in Modified Mayo Score (MMS) at Week 10(Least Squares Mean) = -1.52 units on a scale (95% Confidence Interval, -2.14 to -0.90); Change From Baseline in Modified Mayo Score (MMS) at Week 10(Least Squares Mean): Least Square Mean Difference = -0.90(95% CI, -1.73 to -0.06), P-Value = 0.036; Least Square Mean Difference = -1.16(95% CI, -2.12 to -0.19), P-Value = 0.019; Change From Baseline in Modified Mayo Score (MMS) at Week 10(Least Squares Mean): Least Square Mean Difference = -0.90(95% CI, -1.73 to -0.06), P-Value = 0.036; Least Square Mean Difference = -1.16(95% CI, -2.12 to -0.19), P-Value = 0.019.
- A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE) (Phase 2): the indexed record reports AE = 15 Participants; AE = 11 Participants; -.
- A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis (Phase 2): the indexed record reports Change From Baseline in Modified Mayo Score (MMS) at Week 12(Least Squares Mean): LS Mean Difference = -0.18(90% CI, -1.33 to 0.97); LS Mean Difference = 0.12(90% CI, -1.03 to 1.28); Change From Baseline in Modified Mayo Score (MMS) at Week 12(Least Squares Mean) = -2.11 score on a scale (Standard Error, 0.59); Change From Baseline in Modified Mayo Score (MMS) at Week 12(Least Squares Mean) = -1.98 score on a scale (Standard Error, 0.40).
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Upadacitinib hemihydrate (Approved; JAK1), FG-M701 (Phase 1; TL1A), Risankizumab-RZAA (Approved; IL-23p19), AC-101 (Phase 2; RIPK2). Company & Deal Intelligence records identify sponsor context for AbbVie, Inc. (ABBV), Accro Bioscience (Suzhou) Co., Ltd.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Standard definitions for steroid-free remission and durable disease control.
- Head-to-head trials against current targeted standards, not placebo alone.
- Biomarker strategies that distinguish mechanistic responders before prolonged treatment.
- Long-term infection, malignancy and immune-reconstitution follow-up.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Ulcerative Colitis has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
